Form 4: Parabilis Medicines Insider Trading Update

SEC Form 4 filing reveals significant stock transactions by Guy Levy and associated Soleus entities on June 11, 2026.

Summary

• Guy Levy, identified as a director and 10% owner of Parabilis Medicines, Inc. (PBLS), along with several affiliated Soleus entities, reported transactions on June 11, 2026.
• These transactions involved the acquisition of 375,000 shares of common stock at $20 per share and 125,000 shares of common stock at $20 per share.
• Additionally, 527,070 shares of common stock were acquired at $9.48 per share, which resulted from the conversion of Series F Preferred Stock.
• Following these transactions, the reporting persons beneficially own a substantial number of shares, with specific holdings detailed in the filing.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this filing positively due to significant stock acquisitions by a 10% owner and director, suggesting strong insider confidence.

Positives

• Acquisition of a significant number of common stock shares by a key insider and associated entities, indicating continued investment and confidence in the company.
• Conversion of preferred stock into common stock, potentially signaling a step towards a more streamlined capital structure or a liquidity event like an IPO.

Future Outlook

No specific forward-looking statements or guidance were provided in this Form 4 filing, which primarily reports past transactions.

Industry Context

StockSavvy.ai notes that Form 4 filings are crucial for understanding insider activity. Significant purchases by directors and major shareholders, as seen here, can often be interpreted as a positive signal regarding their belief in the company's future prospects, especially in the biotechnology sector where such investments can be substantial.

Stakeholder Impact

• Shareholders may view the significant stock purchases by insiders as a positive indicator of management's confidence in the company's future performance.
• The transactions could influence investor sentiment and potentially impact the stock price.

Key Dates

Recommendation

The filing indicates significant insider buying, which is generally a positive sign. However, as this is a Form 4 reporting past transactions and not a strategic update or earnings release, a 'hold' recommendation is appropriate pending further information on the company's operational performance and future outlook.

Keywords

SEC Form 4, Insider Trading, Beneficial Ownership, Parabilis Medicines, PBLS, Guy Levy, Soleus Capital Management, Common Stock, Preferred Stock Conversion